Portal de Periódicos da CAPES

Current Status of Clopidogrel Pharmacogenomics

2012; Future Medicine; Volume: 13; Issue: 15 Linguagem: Inglês

10.2217/pgs.12.153

1744-8042

Betti Giusti, Anna Maria Gori, Rossella Marcucci, Rosanna Abbate,

Diabetes Treatment and Management

PharmacogenomicsVol. 13, No. 15 EditorialCurrent status of clopidogrel pharmacogenomicsBetti Giusti, Anna Maria Gori, Rossella Marcucci & Rosanna AbbateBetti Giusti* Author for correspondenceDepartment of Medical & Surgical Critical Care, University of Florence – Atherothrombotic Diseases Center, Careggi Hospital, Largo Brambilla 3, 50134 Florence, Italy. , Anna Maria GoriDepartment of Medical & Surgical Critical Care, University of Florence – Atherothrombotic Diseases Center, Careggi Hospital, Largo Brambilla 3, 50134 Florence, Italy and Don Carlo Gnocchi Foundation, Scientific Institute, Florence, Italy, Rossella MarcucciDepartment of Medical & Surgical Critical Care, University of Florence – Atherothrombotic Diseases Center, Careggi Hospital, Largo Brambilla 3, 50134 Florence, Italy & Rosanna AbbateDepartment of Medical & Surgical Critical Care, University of Florence – Atherothrombotic Diseases Center, Careggi Hospital, Largo Brambilla 3, 50134 Florence, ItalyPublished Online:21 Nov 2012https://doi.org/10.2217/pgs.12.153AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: acute coronary syndromeantiaggregantbioinformaticsclopidogrelgenetic testingpharmacogeneticspharmacogenomicspredictive algorithmsReferences1 Bonello L, Tantry US, Marcucci R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol.56(12),919–933 (2010).Crossref, Medline, CAS, Google Scholar2 Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel nonresponsiveness and risk of cardiovascular morbidity: an updated meta-analysis. Thromb. Haemost.103(4),841–848 (2010).Crossref, Medline, CAS, Google Scholar3 Parodi G, Marcucci R, Valenti R et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA306(11),1215–1223 (2011).Crossref, Medline, CAS, Google Scholar4 Giusti B, Gori AM, Marcucci R, Saracini C, Vestrini A, Abbate R. Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmacogenom. Person. Med.3,33–50 (2010).Crossref, Medline, CAS, Google Scholar5 Krishna V, Diamond GA, Kaul S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. Circulation125(10),1288–1303 (2012).Crossref, Medline, Google Scholar6 Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation125(10),1276–1287 (2012).Crossref, Medline, Google Scholar7 Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357,2001–2015 (2007).Crossref, Medline, CAS, Google Scholar8 Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.361,1045–1057 (2009).Crossref, Medline, CAS, Google Scholar9 Giusti B, Gori AM, Marcucci R et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics17,1057–1064 (2007).Crossref, Medline, CAS, Google Scholar10 Paré G, Mehta SR, Yusuf S et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med.363(18),1704–1714 (2010).Crossref, Medline, CAS, Google Scholar11 Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P4502C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J.11(3),199–206 (2011).Crossref, Medline, CAS, Google Scholar12 Hulot JS, Collet JP, Silvain J et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J. Am. Coll. Cardiol.56(2),134–143 (2010).Crossref, Medline, CAS, Google Scholar13 Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA304(16),1821–1830 (2010).Crossref, Medline, CAS, Google Scholar14 Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA306(24),2704–2714 (2011).Crossref, Medline, CAS, Google Scholar15 Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation121(4),512–518 (2010).Crossref, Medline, CAS, Google Scholar16 Mega JL, Close SL, Wiviott SD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet376(9749),1312–1319 (2010).Crossref, Medline, CAS, Google Scholar17 Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet376(9749),1320–1328 (2010).Crossref, Medline, CAS, Google Scholar18 Bouman HJ, Schömig E, van Werkum JW et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med.17(1),110–116 (2011).Crossref, Medline, CAS, Google Scholar19 Cayla G, Hulot JS, O'Connor SA et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA306(16),1765–1774 (2011).Crossref, Medline, CAS, Google Scholar20 Roberts JD, Wells GA, Le May MR et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet379(9827),1705–1711 (2012).Crossref, Medline, CAS, Google Scholar21 Campo G, Parrinello G, Ferraresi P et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J. Am. Coll. Cardiol.57(25),2474–2483 (2011).Crossref, Medline, CAS, Google Scholar22 Saracini C, Vestrini A, Galora S, Armillis A, Abbate R, Giusti B. Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing. Genet. Test. Mol. Biomarkers16(6),500–503 (2012).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByPharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine1 April 2019 | Genes, Vol. 10, No. 4Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stentInternational Journal of Cardiology, Vol. 225Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplastyXando Díaz-Villamarín, Cristina Lucía Dávila-Fajardo, Luis Javier Martínez-González, Pedro Carmona-Sáez, Jesús Sánchez-Ramos, María Jesús Álvarez Cubero, Luis Miguel Salmerón-Febres, Jose Cabeza Barrera & Fidel Fernández-Quesada27 July 2016 | Pharmacogenomics, Vol. 17, No. 12Non-traumatic splenic rupture on dual antiplatelet therapy with aspirin and ticagrelor after stenting for acute coronary syndromeJournal of Cardiology Cases, Vol. 12, No. 3Clinical Association Between Pharmacogenomics and Adverse Drug Reactions21 April 2015 | Drugs, Vol. 75, No. 6Pharmacogenetic landscape of clopidogrel in north Indians suggest distinct interpopulation differences in allele frequenciesAnil K Giri, Nazir M Khan, INDICO, Analabha Basu, Nikhil Tandon, Vinod Scaria & Dwaipayan Bharadwaj5 May 2014 | Pharmacogenomics, Vol. 15, No. 5Pharmacogenomics of Clopidogrel Vol. 13, No. 15 STAY CONNECTED Metrics Downloaded 424 times History Published online 21 November 2012 Published in print November 2012 Information© Future Medicine LtdKeywordsacute coronary syndromeantiaggregantbioinformaticsclopidogrelgenetic testingpharmacogeneticspharmacogenomicspredictive algorithmsFinancial & competing interests disclosureR Marcucci has received honoraria from Daiichi Sankyo/Eli Lilly and Merck Sharp & Dohme for lectures. R Abbate has received consulting fees from Eli Lilly; lecture fees from Instrumentation Laboratory and Sigma Tau; and research grant funding from Bayer, Boehringer Ingelheim and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download